DIAGENICS is a biopharmaceutical company located in Woburn (Boston), MA (USA) with its European headquarters in Essen, Germany. Our unique business model strives to build a Bridge from Science to Business™.
In this way we aspire to a leading position in the diagnostic field. We are currently focussing on the detection of heart infarction through a new and patented heartmarker.
DIAGENICS constantly observes scientific results and compares them with the needs of market and economy.
Thus, many promising projects are targeted, licensed and quickly developed until they are ready for the market. With DIACORDON™, DIAGENICS has already launched its first product line for the diagnosis of infarction. Besides the development of a sophisticated ACS biochip device DAGENICS plans to widen its supply with projects on stroke diagnosis.
|
|
Rapid diagnosis of heart attack:
clinical trials in Belgrade
 The DIACORDON product line developed by DIAGENICS is applied in a clinical trial at the institute for cardiovascular diseases in Belgrade, Serbia presently. The clinical trial is based on the patent evidence of the body’s enzyme glycogen-phosphorylase isoenzyme BB (GPBB). During an ischemia the enzyme GPBB is mobilized and released into the blood.
|
|
Read more...
|
|
How it works: GPBB: Flash-Animation
Take a look on how our DIACORDON™ Product line works. In our little Flash-Movie we show you the background of our Diacordon™ technology.
Click here to start.
|
|
|
